Switch Therapeutics Inc. has announced its first development candidate, a liver-sparing APOE (apolipoprotein E) RNAi therapy for treatment of Alzheimer’s disease in APOE4 carriers. Switch’s ...
James Marlin stood at a crossroads. After a 25-year career in the medical field, primarily in orthopedic sales and surgical ...
Discover a study that examined the efficacy and safety of pemafibrate in 360 patients with MASLD and hypertriglyceridaemia.
Sickle cell disease affects 100,000 in the U.S., especially the Black community. On “The WAOK Morning Show,” Glinda Dames-Fincher discussed how race and socioeconomics impact care.
In 2021, alcohol-related liver cirrhosis accounted for about a quarter of the 46·4 million disability-adjusted life-years (DALYs) lost from liver disease globally, making alcohol a leading cause of ...
Background: Hepatoblastoma, a prevalent malignant liver tumor in children, presents significant management challenges in ...
SEQUANA MEDICAL ANNOUNCES UPDATE ON SECOND TRANCHE OF CONVERTIBLE BRIDGE LOAN Ghent, Belgium – 2 December 2024 – (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the ...
AKI - the other main type of kidney disease - can be caused by dehydration, blood loss, urinary tract obstructions such as ...
Explore how E-selectin-targeted polymer-doxorubicin therapy induces regression in colorectal liver metastases.
As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...
Scientists from the Department of Energy’s Pacific Northwest National Laboratory have found that long-term heavy drinking can ...
Dr. Ben Galyardt told Newsweek: "There is no drug that will treat fatty liver. There is no surgery that will fix it." ...